The population density of Delaware was 487 in 2018. The population density of Rhode Island was 1,022 in 2018.
Population Density
Population Density is computed by dividing the total population by Land Area Per Square Mile.
Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API -
Geographic and Population Datasets Involving Delaware or Rhode Island
- API
Tourism Nova Scotia Visitation
data.novascotia.ca | Last Updated 2024-05-07T12:42:22.000ZNumber of non resident overnight visitors to Nova Scotia. The dataset is broken down by visitor origin and mode of entry to the province. Data is reported monthly.
- API
Quarantine_SpottedLanternfly
data.pa.gov | Last Updated 2023-02-25T20:08:37.000ZQuarantine_SpottedLanternfly
- API
Incidence Rate Of Leukemia Per 100,000 All States
opendata.utah.gov | Last Updated 2019-04-19T00:30:16.000ZIncidence Rate Of Leukemia Per 100,000 All States
- API
Inmate Population
data.delaware.gov | Last Updated 2024-05-01T10:30:19.000ZThe Delaware Department of Correction (DOC) operates four prison facilities (Level V), eight quasi-incarceration community corrections facilities that serve as violation of probation centers or work release centers (Level IV), and five Probation & Parole locations (Levels III, II, and I). Offenders may also be supervised while on home confinement, or the offender may be supervised on an administrative basis only while restitution is paid. Some offenders are physically housed at the Delaware Psychiatric Center while in the custody of the DOC. This dataset provides a snapshot of the offender population in custody or under supervision at these various locations on the last day of each calendar month. A count of how many offenders by the year, month (snapshot of last day of month), county, type of institution, institution name, sentence type, gender, race, and ethnicity can be produced by selecting the desired variable in each category. Questions about offender data can be directed to the DOC’s Planning & Research Unit. Instructions for submitting a data request can be found here: http://www.doc.delaware.gov/datarequests.shtml. The DOC’s annual reports (http://www.doc.delaware.gov/annualReport.shtml) also contain a variety of information and data.
- API
Incidence Of Brain And Central Nervous System Cancer Age 15 Under Per 1,000,000 All States
opendata.utah.gov | Last Updated 2019-04-19T01:42:51.000ZIncidence Of Brain And Central Nervous System Cancer Age 15 Under Per 1,000,000 All States
- API
New Brunswick Population Characteristics 1986 -2006 / Caractéristiques de la population du Nouveau-Brunswick 1986 -2006
gnb.socrata.com | Last Updated 2019-07-12T13:06:01.000ZAn overview of population totals for both urban and rural areas of New Brunswick / Un aperçu des totaux de population pour les zones urbaines et rurales du Nouveau-Brunswick
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status
data.cdc.gov | Last Updated 2023-07-20T16:01:58.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
Age Adjusted Incidence Rates Of Bladder Cancer Per 100,000 All States-TEST
opendata.utah.gov | Last Updated 2014-10-20T15:36:15.000ZAge Adjusted Incidence Rates Of Bladder Cancer Per 100,000 All States-TEST
- API
FY 2021_NCVAS Facilities Data For State Including PR
www.datahub.va.gov | Last Updated 2023-08-25T19:44:55.000ZFY2021 VA facilities data provided by the National Center for Veterans Statistics and Analysis, published in 2023 includes PR
- API
Age Adjusted Incidence Rates Of Bladder Cancer Per 100,000 All States
opendata.utah.gov | Last Updated 2019-02-11T20:58:05.000ZAge Adjusted Incidence Rates Of Bladder Cancer Per 100,000 All States